

**Czech Republic - More stringent blood donor testing requirements
2015 Mapping exercise**

Colour key	
	Minimum requirements as set out in the 2004/33/EC Directive
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfusion or plasma for fractionation)	Circumstances for application/ donor profile	Regional differences	Further comments
Basic testing								
Blood group testing	ABO typing	YES	NO	N/A	whole blood/ blood components for transfusion	all donations	NO	
	RhD typing	YES	NO	N/A	whole blood/ blood components for transfusion	all donations	NO	e.g. specific requirement for weak RhD testing
	Other, please specify (Kell etc.)	NO	YES	Blood Transfusion Society http://www.transfuznispolecnost.cz/index.php?page=dokumenty&identifikator_kategorie=DOPORUCENE_POSTUPY	whole blood/ blood components for transfusion	each donor twice	NO	Kell, Rh phenotype: red cells components only
HLA testing								HLA typed platelet donors or HLA cross-matched platelets are available on special request for some groups of patients
Disease testing								
VIRAL								
HIV 1 and HIV 2	Anti-HIV 1	YES	NO	N/A	both	all donations	NO	labile blood components: 2/52 BEs perform NAT in pool (on voluntary basis); plasma for fractionation is tested by fractionating company
	Anti-HIV 2	YES	NO	N/A	both	all donations		
	HIV 1p24	YES	NO	N/A	both	all donations		
	HIV NAT pool or ID	YES	NO	N/A	plasma for fractionation	all donations		
	HIV NAT ID Other technique							
Hepatitis B	HBs Ag	YES	NO	N/A	both	all donations	NO	labile blood components: some BEs test anti-HBc in new donors; 2/52 BEs perform NAT in pool; plasma for fractionation is tested by fractionating company
	Anti-HBc							
	Anti - HBs							
	HBV NAT pool or ID	YES	NO	N/A	plasma for fractionation	all donations		
Hepatitis C	Anti-HCV	YES	NO	N/A	both	all donations	NO	labile blood components: some BEs test HCV Ag (1/3 of all donations); 2/52 BEs perform NAT in pool; plasma for fractionation is tested by fractionating company
	HCV NAT pool or ID	YES	NO	N/A	plasma for fractionation	all donations		
	HCV NAT ID							
	Other technique							
Hepatitis E								
HTLV-1								
HTLV-2								
Ebola Virus								
Chikungunya virus								
Cytomegalovirus								
West Nile Virus*	WNV/ technique not specified						NO	performed by plasma fractionator according to specific requirements of Pharmacopoeia
	WNV NAT pool or ID	YES	NO	N/A	plasma for fractionation	all donations		
	WNV NAT ID							
	Other technique							
Dengue Virus								
Epstein-Barr virus								
Human Parvovirus B19	HPVB19/ technique not specified						NO	performed by plasma fractionator according to specific requirements of Pharmacopoeia
	HPVB19 NAT pool or ID	YES	NO	N/A	plasma for fractionation	all donations		
	HPVB19 NAT ID							
	Other technique							
Herpes simplex								
Nonspecific viral infection								
Other pathogen								
PARASITIC								
Malaria								
Trypanosomiasis								
Babesiosis								
Leishmaniasis								
Toxoplasmosis								
Other pathogen								
BACTERIAL								
Treponema pallidum (Syphilis)	Technique not specified						NO	detection of syphilis + marker of risk behaviour
	Microscopy							

**Czech Republic - More stringent blood donor testing requirements
2015 Mapping exercise**

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfusion or plasma for fractionation)	Circumstances for application/ donor profile	Regional differences	Further comments
	Anti- <i>T. pallidum</i>	YES	NO	N/A	both	all donations		
	<i>T. pallidum</i> NAT pool							
	<i>T. pallidum</i> NAT ID							
	Culture							
	Other technique							
Neisseria								
Brucellosis								
Tuberculosis								
Q-fever								
Other pathogen,								
FUNGI								
specify pathogen								

* For West Nile Virus NAT ID, see 2004/33/EC as amended by 2014/110/EU with a deadline for transposition into national law of December 31, 2015